Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Research article

Association between serum uric acid level and metabolic syndrome components

Authors: Sara Nejatinamini, Asal Ataie-Jafari, Mostafa Qorbani, Shideh Nikoohemat, Roya Kelishadi, Hamid Asayesh, Saeed Hosseini

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Background

Serum uric acid levels is reported to be associated with a variety of cardiometabolic risk factors; however, its direct association with metabolic syndrome (MetS) remains controversial. Thus, we examined the association of serum uric acid concentrations with the MetS components.

Methods

MetS was defined according to the National Cholesterol Education Program (NCEP) criteria. This case–control study comprised 101 non-smoking individuals (41 in the MetS group and 60 in the non-MetS group). Blood pressure, fasting plasma glucose, insulin, HOMA-IR, lipid profiles, uric acid, and anthropometric measures were determined, and body composition was assessed by using bioelectrical impedance analysis (BIA).

Results

After adjustment for confounding factors, serum uric acid was significantly higher in MetS group than non-MetS group (5.70 ± 1.62 vs 4.97 ± 1.30 mg/dL, respectively, P = 0.001). After controlling for age, sex and body mass index in partial correlation analysis, uric acid was positively correlated with triglycerides, and negatively with HDL-C. In multiple logistic regression analysis, every 1 mg/dl elevation in the serum uric acid level increased the risk of MetS approximately by 2-folds (OR: 2.11, 95 % CI: 1.30-3.41).

Conclusion

This study showed that those individuals with MetS have higher uric acid levels; the association of uric acid and MetS components supports that it might be an additional components of MetS.
Literature
1.
Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. National heart, lung, and blood institute; american heart association. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/ american heart association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef
2.
Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.PubMedCrossRef
3.
Ramakrishna V, Jailkhani R. Oxidative stress in noninsulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008;45:41–6.PubMedCrossRef
4.
Fu CC, Wu DA, Wang JH, Yang WC, Tseng CH. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol. 2009;46:127–34.PubMedCrossRef
5.
Guo L, Cheng Y, Wang X, Pan Q, Li H, Zhang L, et al. Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality. Acta Diabetol. 2012;49 Suppl 1:S65–71.PubMedCrossRef
6.
Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA. 2000;283:221–8.PubMedCrossRef
7.
Nestel P, Lyu R, Low LP, Sheu WH, Nitiyanant W, Saito I, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr. 2007;16:362–7.PubMed
8.
Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the middle east: the national survey of risk factors for non-communicable diseases of Iran. Diabetes Care. 2009;32:1092–7.PubMedPubMedCentralCrossRef
9.
Chiou WK, Wang MH, Huang DH, Chiu HT, Lee YJ, Lin JD. The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. J Epidemiol. 2010;20:219–24.PubMedPubMedCentralCrossRef
10.
Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27:1174–81.PubMedCrossRef
11.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Zimmet P; expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.PubMedCrossRef
12.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
13.
Reimann M, Schutte AE, Malan L, Huisman HW, Malan NT. Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: a factor analysis. Atherosclerosis. 2008;197:638–45.PubMedCrossRef
14.
Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845–52.PubMedPubMedCentralCrossRef
15.
Numata T, Miyatake N, Wada J, Makino H. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract. 2008;80:1–5.CrossRef
16.
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.PubMedCrossRef
17.
Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635–39.PubMedCrossRef
18.
Zhang Q, Zhang C, Song X, Lin H, Zhan D, Meng W, et al. A longitudinal cohort based associationstudy between uric acid level and metabolic syndrome in Chinese Hanurban male population. BMC Public Health. 2012;12:419.PubMedPubMedCentralCrossRef
19.
Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8:593–8.PubMedPubMedCentralCrossRef
20.
Gersch C, Palii SP, Kim M, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008;27:967–78.PubMedPubMedCentralCrossRef
21.
Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003;285:123–9.CrossRef
22.
Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73:1059–64.PubMedCrossRef
23.
Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:227–33.PubMedCrossRef
24.
Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemio. 2003;18:523–30.CrossRef
25.
Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men with-out metabolic syndrome. Hypertension. 2007;49:298–303.PubMedCrossRef
26.
Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Associations of serum uric Acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83–9.PubMedCrossRef
27.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–9.PubMedCrossRef
28.
Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol. 1998;138:63–9.PubMedCrossRef
29.
Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:9.PubMedPubMedCentralCrossRef
30.
31.
Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47:929–33.PubMedCrossRef
32.
Silva HA, Carraro JC, Bressan J, Hermsdorff HH. Relation between uric acid and metabolic syndrome insubjects with cardiometabolic risk. Einstein (Sao Paulo). 2015;13:202–8.
33.
Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20:1029–33.PubMedPubMedCentralCrossRef
34.
Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism. 1996;45:699–706.PubMedCrossRef
35.
Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence ofhyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;25(4):9.CrossRef
36.
Desai MY, Santos RD, Dalal D, Carvalho JA, Martin DR, Flynn JA, et al. Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. Am J Cardiol. 2005;95:865–8.PubMedCrossRef
37.
Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med. 2007;46:1353–8.PubMedCrossRef
38.
Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, et al. Is hyperuricemia another facet of the metabolic syndrome? J Chin Med Assoc. 2006;69:104–9.PubMedCrossRef
39.
Sheu WH, Tseng YH. Uric acid: an additional component of metabolic syndrome? J Chin Med Assoc. 2006;69:99–100.PubMedCrossRef
40.
Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007;17:245–52.PubMedCrossRef
41.
Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845–52.PubMedPubMedCentralCrossRef
42.
Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038–44.PubMedCrossRef
43.
Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Korean. Korean Circ J. 2010;40:314–20.PubMedPubMedCentralCrossRef
44.
Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006;69:512–6.PubMedCrossRef
45.
Kim SK, Park HA, Nam OY, Beck SH, Whang DH, Hwang UK, et al. Risk of the metabolic syndrome according to the level of the uric acid. J Korean Acad Fam Med. 2007;28:428–35.
46.
Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–7.PubMedCrossRef
47.
Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19:1055–62.PubMedCrossRef
48.
Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–52.PubMedCrossRef
49.
Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–51.PubMedCrossRef
50.
Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1:80–6.PubMedCrossRef
Metadata
Title
Association between serum uric acid level and metabolic syndrome components
Authors
Sara Nejatinamini
Asal Ataie-Jafari
Mostafa Qorbani
Shideh Nikoohemat
Roya Kelishadi
Hamid Asayesh
Saeed Hosseini
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-015-0200-z

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue

Letter to the Editor

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Research article

Diabetes care among elderly medicare beneficiaries with Parkinson’s disease and diabetes

Research article

Effect of the different assays of HbA1c on diabetic patients monitoring

Research article

Effects of predisposing, reinforcing and enabling factors on self-care behaviors of the patients with diabetes mellitus in the Minoodasht city, Iran

Research article

The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy

Research article

The association between bone health indicated by calcaneal quantitative ultrasound and metabolic syndrome in Malaysian men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits